Photo: MoMo Productions/Getty Images
Oura has launched its first proprietary large language model designed to deliver personalized women's health guidance, marking a shift toward more specialized AI capabilities built on biometric data and clinician-reviewed medical knowledge.
The model is being released for testing through Oura Labs, the company's experimental feature platform, and is integrated into the Oura Advisor tool within the Oura app.
It is designed to provide health guidance based on a combination of established medical standards, clinician-curated research and individual biometric data collected through the company's wearable ring.
The system supports a range of reproductive and hormonal health topics, including menstrual cycles, pregnancy and menopause. It analyzes longitudinal biometric signals, such as sleep patterns, activity levels, stress indicators and cycle tracking data, to generate individualized responses.
Dr. Tanvi Jayaraman, clinical lead of health AI at Oura, told MobiHealthNews the model is grounded in established medical standards and clinical research that have been reviewed by Oura's in-house team of board-certified clinicians and women’s health experts.
"The model is interpreting questions through the lens of what's happening in that person's body, not just a generic symptom search," she explained.
The result is guidance that is more context-aware, more aligned with how women experience their health and delivered within a privacy-first environment on Oura-controlled infrastructure.
"Between [doctor's] visits, women aren't starting from a blank page," Jayaraman said. "If someone notices new symptoms or a change in their cycle, Oura Advisor can help them understand what's typical, what their longitudinal data may indicate, and which details are most important to track and bring to their clinician – without diagnosing or replacing care."
In practical terms, they can walk into an appointment with months of organized trends, clearer questions and a better sense of what they want to discuss, which can make limited time with providers more focused, collaborative and effective.
The model is part of the broader Advisor platform, which combines generative AI with biometric monitoring and health algorithms.
When users submit questions, the system draws on curated medical knowledge and the user's historical biometric data to generate responses contextualized to their physiology and health patterns.
The company is initially deploying the model through its Oura Labs testing program, which allows users to opt in voluntarily. The model is hosted on its own infrastructure, and user conversations are not shared with third-party systems or used to train public AI models.
Oura said it plans to use feedback from the testing program to refine the model before broader deployment.
THE LARGER TREND
The effort reflects a growing trend toward specialized healthcare AI models designed to support patient engagement and supplement clinical decision-making with personalized insights derived from wearable device data.
Oura has expanded its role in digital women's health through partnerships with several virtual care and fertility companies, enabling clinicians to incorporate wearable biometric data into care planning and decision support.
In 2025, the company partnered with Maven Clinic, a virtual women's and family health provider, to allow Oura Ring users to sync their biometric data with Maven's platform. The integration gives Maven care teams access to patient data on sleep, stress and activity, which can be used to support reproductive and family health services.
Oura also formed a partnership with Progyny, an employer-focused fertility and family-building benefits provider, to incorporate wearable data into clinical workflows, and Natural Cycles, a digital birth control app, to use wearable-derived temperature data to improve cycle tracking and fertility monitoring.
Oura raised $900 million in October 2025 in a funding round led by Fidelity Management & Research, with participation from ICONIQ, Atreides and Whale Rock. The investment increased the company's valuation to approximately $11 billion.
